Healthcare
BioPorto A/S(THOXF)
Live Price
Offline$0.149
+0.00% today
1Y Change
-48.26%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $600.00M
- Revenue Growth
- +10.9%
- EPS Growth
- +11.8%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioPorto A/S (THOXF) is a Healthcare stock with a market cap of $600.00M and listed on OTC. The stock last traded around $0.15 and down 48.3% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +10.9%, EPS growth of +11.8%, a dividend yield of 0.0%. What stands out right now is revenue +10.9%, EPS +11.8%, free cash flow +8.4% with operating margin -213.7% and ROIC -114.4%. Valuation already assumes a fairly strong business story at price/sales 14.8. Stock Foundry combines THOXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.9% vs +7.6% peer median
Operating Margin
Below sector median
-213.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.9% and EPS at +11.8%, with operating margin around -213.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 26, 2026 | +33.3% | +0.0% | +0.0% | +0.0% |
2025 Aug 15, 2025 | -411.7% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THOXF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
THOXF Max Drawdown
-48.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for THOXF and SPY.
Company Overview
BioPorto A/S
Other OTC
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
- Leadership
- Carsten Buhl
- IPO Date
- Dec 13, 2019
- Employees
- 48
- Street Address
- Tuborg Havnevej 15
- Mailing
- Hellerup, 2900
- Region
- Hellerup, DK
- Reporting Currency
- USD
- Investor Line
- 45 45 29 00 00
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 14.8
- Price/Book
- 9.5
Growth
- Revenue
- +10.9%
- EPS
- +11.8%
- Free Cash Flow
- +8.4%
Profitability
- Gross Margin
- 75.4%
- Operating Margin
- -213.7%
- Net Margin
- -203.8%
- ROE
- -166.9%
- ROIC
- -114.4%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 3.25
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.